Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2967/jnumed.116.178145 | DOI Listing |
Eur J Surg Oncol
August 2021
Department of HPB Surgery, Manchester Royal Infirmary, Manchester, UK.
World J Gastroenterol
March 2021
Medical Oncology Department, The Ramón y Cajal Health Research Institute, Alcalá University, University Hospital Ramon y Cajal, Madrid 28034, Spain.
Background: Somatostatin analogues are an established first-line therapy for well differentiated small bowel neuroendocrine tumours (Wd-SBNETs), while and peptide receptor radionuclide therapy (PRRT) is frequently used as a second-line therapy. Adequate treatment selection of third-line treatment remains challenging due to the limited prospective data currently available on the best therapeutic sequence.
Aim: To understand current practice and rationale for decision-making by physicians in the 3-line setting by building an online survey.
JAMA Surg
October 2020
Department of Gastroenterological Surgery, University of Helsinki, Helsinki, Finland.
Lancet Diabetes Endocrinol
July 2019
Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.
J Nucl Med
March 2019
National Institutes of Health 35A Convent Dr., GD937 Bethesda, MD 20892-3759 E-mail:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!